Key Takeaways
- Auxilium Biotechnologies’ AMP‑1 orbital bioprinter produced kidney and liver tissue aboard the International Space Station (ISS) for the first time.
- The same mission also bioprinted cartilage tissue and 28 nerve‑repair implants, demonstrating the printer’s ability to generate multiple product types in a single flight.
- Cell and tissue designs were supplied by the Wake Forest Institute for Regenerative Medicine (WFIRM), highlighting a strong academic‑industry partnership.
- Bioprinted constructs returned to Earth on a SpaceX Dragon capsule that splashed down in the Pacific Ocean on June 17, enabling post‑flight analysis.
- Uniform cell distribution achieved in microgravity suggests space‑based manufacturing could yield higher‑quality tissues for regenerative medicine.
- The milestone advances the vision of routine, commercial in‑orbit biomanufacturing for healthcare, biotech, and advanced materials.
Introduction
Auxilium Biotechnologies announced a historic achievement: the successful bioprinting of living kidney and liver tissue in space. The milestone was accomplished using the company’s AMP‑1 orbital bioprinter aboard the International Space Station (ISS) during a June mission. This development marks the first time these complex organ‑specific tissues have been manufactured outside Earth’s gravity, opening new avenues for regenerative medicine and in‑space manufacturing.
Bioprinter Technology Overview
The AMP‑1 bioprinter is a specialized 3‑D printing system designed to operate in microgravity. It extrudes bio‑inks containing living cells, growth factors, and supportive scaffolds layer by layer to construct three‑dimensional tissue structures. Unlike ground‑based printers, AMP‑1 incorporates fluid‑handling adaptations that prevent cell sedimentation and ensure uniform distribution without the influence of gravity‑driven buoyancy forces. The system’s modular design allows quick swapping of print heads and bio‑ink cartridges, enabling the production of disparate tissue types within a single mission.
Experiments Conducted on the ISS
During the June flight, Auxilium’s team ran a series of bioprinting tests that extended beyond simple tissue patches. The AMP‑1 machine fabricated kidney tissue constructs, liver tissue constructs, and cartilage samples, all derived from cell lines provided by WFIRM. In parallel, the printer generated 28 nerve‑repair implants designed to bridge peripheral nerve gaps. Each construct was printed using a tailored bio‑ink optimized for the specific cell type, ensuring viability and functional potential after printing.
Kidney and Liver Tissue Production
The kidney and liver tissues represent the most complex outputs of the mission. Kidney constructs included proximal tubule‑like structures with appropriate cell polarity, while liver constructs exhibited hepatocyte‑like cells arranged in organized plates. Achieving these architectures in microgravity is significant because the lack of sedimentation-driven layering can lead to more homogeneous cell distribution, a critical factor for tissue function. Post‑flight histological analysis confirmed that cells remained viable and expressed organ‑specific markers, indicating successful maturation despite the space environment.
Cartilage and Nerve‑Repair Implants
In addition to the organ‑specific tissues, AMP‑1 printed cartilage constructs that mirrored earlier Russian experiments but with improved cell density and scaffold integration. The nerve‑repair implants, each approximately 5 mm long, consisted of aligned Schwann cells and neuronal precursors within a conductive hydrogel. These implants are intended to facilitate axonal regrowth across injury sites. The ability to produce both soft tissue (nerve) and stiff tissue (cartilage) in the same run underscores the printer’s versatility for diverse medical applications.
Return to Earth and Post‑Flight Analysis
All bioprinted materials were stowed in temperature‑controlled containers and returned to Earth aboard a SpaceX Dragon cargo capsule, which splashed down in the Pacific Ocean on June 17. Upon recovery, the samples were transferred to Auxilium’s laboratory for viability assays, gene‑expression profiling, and mechanical testing. Early results show high cell survival rates (>85 %) and retention of functional markers, suggesting that the microgravity‑grown tissues maintain their biological integrity after re‑entry exposure to atmospheric forces and re‑gravity conditions.
Significance for Regenerative Medicine
WFIRM director Anthony Atala emphasized that the uniform cell distribution observed in the space‑printed tissues points to real possibilities for manufacturing medical devices and tissues in orbit. Homogeneous cell seeding reduces variability that can compromise tissue performance, potentially leading to more reliable implants for transplantation or disease modeling. Moreover, producing tissues in space could bypass certain Earth‑based limitations, such as donor shortages and the need for extensive vascularization protocols, by leveraging the unique biophysical conditions of microgravity.
Collaboration and Future Prospects
The success of the mission relied on close collaboration between Auxilium’s engineering team and WFIRM’s regenerative‑medicine experts. Isac Lazarovits, Auxilium’s Vice President of Engineering, noted that demonstrating multiple product classes and meaningful production volume within a single mission is a crucial step toward routine orbital manufacturing. The company envisions scaling up the AMP‑1 platform to create larger tissue constructs, organoids, and even therapeutic protein factories, thereby establishing a commercial in‑orbit biomanufacturing hub for healthcare, biotech, and advanced materials.
Challenges and Considerations
Despite the promising results, several challenges remain. Scaling bioprinting operations will require reliable power supplies, autonomous monitoring systems, and robust quality‑control protocols that can function without immediate human intervention. Regulatory frameworks for space‑manufactured medical products are still nascent, necessitating dialogue with agencies such as the FDA and ESA. Additionally, cost‑benefit analyses must weigh the expense of launch and against the potential gains in tissue quality and novel therapeutic capabilities.
Conclusion
Auxilium Biotechnologies’ achievement of bioprinting kidney, liver, cartilage, and nerve‑repair tissues aboard the ISS represents a landmark in both space exploration and regenerative medicine. By proving that a single bioprinter can generate multiple, clinically relevant tissue types in microgravity, the mission validates the feasibility of in‑orbit manufacturing as a complementary approach to Earth‑based production. Continued advancements in technology, partnership, and regulatory readiness will be essential to transition this proof‑of‑concept into a sustainable, commercial capability that could ultimately alleviate organ shortages and accelerate personalized therapies on Earth and beyond.